The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be conducted in non-menopausal female and male subjects who are on glucagon-like peptide-1 (GLP-1) agonist therapy for weight loss.
Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
Adult men and women aged 25-50 years.
Fitzpatrick skin types I-IV.
Current treatment with a stable dose of GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least last 6 months.
Pregnancy or planned pregnancy during the study or currently breastfeeding.
Current menopausal state.
Any uncontrolled systemic disease.
Current use of other GLP-1 agonist therapy aside from the GLP-1 agonist class of medications (Ozempic, Rybelsus, or Wegovy).
Goldman, Butterwick, Fitzpatrick and Groff
Lead sponsor
L'Oreal
Collaborator